Superworth

TriSalus Life Sciences price to book ratio TLSI

Market value divided by the book value of the company's net assets, since 2021.

Today, Oct 23, 2026
33.7×
5-year median
31.0×
Against its 5-year history
51st
percentile: 0 is its lowest day, 100 its highest
5-year range
11.2× to 62.2×
Peer median
2.4×

TriSalus Life Sciences' price to book ratio is 33.7× as of Oct 23, 2026.

That is above its 5-year median of 31.0×, close to the middle of its last 5 years.

Over that time it ranged from 11.2× in Dec 2023 to 62.2× in Nov 2021.

The median for 10 medical instruments and supplies stocks of a similar size is 2.4×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far33.7×12.9×52.7×
2025n/m a value too high to mean anything
202430.4×26.3×31.0×
202326.2×11.2×27.1×
2022n/m a value too high to mean anything
202162.2×60.5×62.2×

Against its peers

Companies in Medical - Instruments & Supplies nearest TriSalus Life Sciences' size, closest first, today.

CompanyPrice to book ratio
TLSITriSalus Life Sciences33.7×
UTMDUtah Medical Products1.9×
PDEXPro DEX4.2×
INFUInfuSystem4.7×
EMBCEmbectan/m
KEQUKewaunee Scientific1.3×
TCMDTactile Systems Technology2.4×
MDXGMimedx2.6×
MOVMovado1.4×
APTAlpha Pro Tech0.9×
IRMDIradimed10.8×
Peer median2.4×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on TriSalus Life Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.